Karyopharm Therapeutics | KPTI - Current Liabilities


Karyopharm Therapeutics reported $117.3M in Current Liabilities for its fiscal quarter ending in March of 2026.





Current Liabilities Change Date
AbbVie USD 41.64B 458M Jun/2026
Abbott USD 18.38B 1.88B Mar/2026
Amgen USD 25.5B 547M Jun/2026
AstraZeneca USD 31.55B 1.02B Jun/2026
BioCryst Pharmaceuticals USD 208.85M 13.46M Jun/2026
Bristol-Myers Squibb USD 18.66B 499M Jun/2026
Eli Lilly USD 47.74B 11.11B Jun/2026
Enanta Pharmaceuticals USD 44.73M 3.83M Dec/2025
GlaxoSmithKline GBP 21.53B 895M Jun/2026
Incyte USD 1.31B 177.55M Jun/2026
J&J USD 54.9B 2.82B Jun/2026
Karyopharm Therapeutics USD 117.3M 25.24M Mar/2026
MacroGenics USD 108.82M 12.88M Jun/2026
Merck USD 27.73B 786M Jun/2026
Nektar Therapeutics USD 57.71M 4.17M Mar/2026
Novartis USD 31.75B 374M Jun/2026
Novartis USD 31.37B 4.1B Mar/2026
Pfizer USD 32.65B 1.7B Jun/2026
Regeneron Pharmaceuticals USD 5.53B 422.9M Jun/2026
Roche Holding CHF 28.85B 846M Jun/2026
Sangamo BioSciences USD 47.66M 1.9M Jun/2025
Takeda JPY 2.76T 335.02B Jun/2026
Tectonic Therapeutic USD 12.96M 3.29M Mar/2026
TG Therapeutics USD 268.49M 81.38M Jun/2026
Ultragenyx Pharmaceutical USD 351M 26M Jun/2026
Xencor USD 81.86M 8.41M Jun/2026